Bristol-Myers Squibb discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers products for diseases in hematology, oncology, cardiovascular, immunology, fibrosis and neuroscience. The company’s products include Eliquis for stroke/systemic embolism risk reduction in non-valvular atrial fibrillation and treatment of DVT/PE; Opdivo for various anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, gastric and esophageal cancers; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company also offers Yervoy for the treatment of patients with unresectable or metastatic melanoma, Empliciti for the treatment of multiple myeloma, Abecma for relapsed or refractory multiple myeloma, Reblozyl for the treatment of anemia, Opdualag for the treatment of unresectable or metastatic melanoma, and Zeposia for the treatment of relapsed multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma, Onureg for the treatment of AML, Inrebic for the treatment of myelofibrosis, Camzyos for symptomatic obstructive HCM to enhance functional capacity and symptoms, Sotyktu for the treatment of moderate to severe plaque psoriasis, Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, and Revlimid, an oral immunomodulatory agent for the treatment of multiple myeloma. The company manufactures Abraxane for the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer. The company sells its products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Home page
Source link